PharmaMar looks to accelerate oncology research with AI through collaboration with Globant

Core Insights - PharmaMar and Globant have announced a collaboration aimed at accelerating cancer drug discovery using artificial intelligence [1][8] - The partnership leverages a multi-agent AI system that achieves over 90% accuracy in data retrieval and can reduce time to insights by up to 15 times [2][8] AI for Cancer Drug Discovery - The AI system developed by Globant is capable of analyzing extensive scientific, regulatory, and clinical data to support decision-making within PharmaMar's R&D ecosystem [3] - More than 20 specialized digital agents are employed across various areas including preclinical, clinical, regulatory, and commercial, enhancing the efficiency of cancer research [4] Efficiency and Decision-Making - The AI system can review over 4,500 research documents to prioritize the 10 most viable treatment-indication combinations from over 8,000 possibilities, significantly reducing the time required for human researchers [5] - This integration allows PharmaMar to make faster and more informed decisions regarding promising treatment combinations [5] Future Developments - PharmaMar plans to extend the AI capabilities to include hypothesis generation, real-time compliance checks, and automated content creation for scientific reporting [6] - The collaboration aims to foster a culture of digital innovation within PharmaMar, enhancing its ability to leverage institutional knowledge [6] Impact on Drug Discovery - The partnership exemplifies the potential of combining human intelligence with AI systems to create a new model for drug discovery that emphasizes precision and scalability [7]